Protocol Ledger

NCT04896008 · Phase III · COMPLETED

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

Interventional Phase III clinical trial protocol NCT04896008 sponsored by Merck & Co. in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-01 Enrollment: 173 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04896008
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)173 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04896008
Protocol FieldVerified Registry Value
NCT IdentifierNCT04896008
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment173 participants (ACTUAL)
Registered Start Date2021-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI